TP53 and cancer: Using the website tool of Comprehensive Analysis on Multi-Omics of Immunotherapy in pan-cancer (CAMOIP) [17], we found that the frequencies of mutations in several tumor suppressor genes (e.g., TP53 and PTEN) and oncogenes (e.g., CTNNB1) were unequally distributed in the ERFEhigh versus ERFElow groups.